Search

everythinglearnresearchcommunity

for

Search:↓

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Promising cancer treatments were found, but the manufacturer closed.

Inhibiting TYK2 can restore hair growth in alopecia areata.

PEVIII is a promising treatment for Pseudomonas aeruginosa keratitis.

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

Blocking certain immune signals can reduce skin damage from radiation therapy.

Tideglusib helps heal wounds in older skin.

Caizhixuan hair tonic helps treat hair loss by promoting hair growth and improving hair follicles.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

JAK inhibitors may soon be a safe and effective treatment for alopecia areata.

Janus kinase inhibitors are effective and safe for treating alopecia areata.

Tofacitinib is effective and safe for treating alopecia areata.

A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

Applying a specific inhibitor lightens skin and hair color.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Baricitinib is effective in promoting hair growth in severe alopecia areata.

Oral JAK inhibitors help regrow hair in alopecia patients.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Topical tacrolimus reduces certain growth factors in hair follicles.

Tofacitinib effectively improved severe skin symptoms in a patient with Hypohidrotic Ectodermal Dysplasia.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.

Keratin 6A increases skin inflammation, suggesting it could be a target for treating certain skin diseases.

Blocking TYK2 might be a new way to treat hair loss from alopecia areata.